Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Directed against SARS Coronavirus Nucleocapsid (N) protein. The product was purified from monospecific antiserum by protein A affinity purification. BLAST analysis was used to suggest reactivity with related Coronavirus proteins. Cross reactivity with homologues from other sources has not been determined.
Severe Acute Respiratory Syndrome (SARS), an emerging disease characterized by atypical pneumonia, has recently been attributed to a novel coronavirus (SARS-CoV). The nucleocapsid protein (N) was one of the structural proteins of SARS-CoV (N, S, sE, M). The severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid (N) protein is the most abundant protein in the virus-infected cells. The SARS-CoV-2 S gene has 76% amino acid similarity to the SARS-CoV S gene, and nonsynonymous mutations developed in the S protein as the SARS-CoV epidemic developed, reports have shown that the crystal structure of the SARS-CoV-2 nucleocapsid protein is similar to those of previously described coronavirus N proteins, but their surface electrostatic potential characteristics are distinct.
Protein Aliases: Coronavirus; COVID; COVID 19; COVID-19; COVID19; SARS; SARS Coronavirus; SARS CoV; SARS CoV-2; SARS CoV2; SARS Nucleocapsid; SARS-CoV-2; SARS-CoV2